PROBLEMS AND PERSPECTIVES OF ANTIBACTERIAL THERAPY OF CHRONIC PSEUDOMONAS INFECTION IN PATIENTS WITH CYSTIC FIBROSIS

PROBLEMS AND PERSPECTIVES OF ANTIBACTERIAL THERAPY OF CHRONIC PSEUDOMONAS INFECTION IN PATIENTS WITH CYSTIC FIBROSIS

Show other versions (1)

Authors analyze the data on effectiveness and safety of new regimen of combined antibacterial therapy with solution of tobramycin for inhalations 300 mg/5 ml (Tobi). This drug was administered to 23 patients with cystic fibrosis during 15 days at the time of an exacerbation. It was shown that additi...

Full description

Bibliographic Details
Main Authors:	S.Yu. Semykin, S.S. Postnikov, S.V. Polikarpova, L.G. Dubovik, M.A. Sagatelyan
Format:	Article
Language:	English
Published:	"Paediatrician" Publishers LLC 2010-03-01
Series:	Вопросы современной педиатрии
Online Access:	https://vsp.spr-journal.ru/jour/article/view/866

Similar Items

PROBLEMS AND PERSPECTIVES OF ANTIBACTERIAL THERAPY OF CHRONIC PSEUDOMONAS INFECTION IN PATIENTS WITH CYSTIC FIBROSIS
by: S.Yu. Semykin, et al.
Published: (2010-01-01)

SOLUTION OF THE PROBLEM OF PSEUDOMONAS INFECTION IN CHILDREN WITH CYSTIC FIBROSIS
by: O. I. Simonova, et al.
Published: (2014-01-01)

THE PERFORMANCE OF A LONG-TERM ANTIBACTERIAL THERAPY IN CHILDREN WITH CYSTIC FIBROSIS DURING PRIMARY PLATING OF PSEUDOMONAS AERUGINOSA
by: О. I. Simonova, et al.
Published: (2014-12-01)

Isolation of Pseudomonas cepacia in cystic fibrosis patient
by: Elizabeth de Andrade Marques, et al.
Published: (1993-03-01)

Characterization of <it>Pseudomonas aeruginosa </it>isolated from chronically infected children with cystic fibrosis in India
by: Das Bimal, et al.
Published: (2005-07-01)

Alkyl-Quinolones derivatives as potential biomarkers for Pseudomonas aeruginosa infection chronicity in Cystic Fibrosis
by: Serge Michalet, et al.
Published: (2021-10-01)

Interactions between Neutrophils and Pseudomonas aeruginosa in Cystic Fibrosis
by: Balázs Rada
Published: (2017-03-01)

Coinfection with Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis
by: Karen Keown, et al.
Published: (2020-11-01)

Molecular Mechanisms of Staphylococcus and Pseudomonas Interactions in Cystic Fibrosis
by: Lalitha Biswas, et al.
Published: (2022-01-01)

Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis
by: Roger Sord&eacute;, et al.
Published: (2011-01-01)

THE ROLE OF CONNECTIVE TISSUE DYSPLASIA IN CHILDREN’S CYSTIC FIBROSIS. CLINICAL AND GENETIC ASPECTS
by: A. V. Goryainova, et al.
Published: (2018-11-01)

Genetic relatedness and host specificity of Pseudomonas aeruginosa isolates from cystic fibrosis and non-cystic fibrosis patients
by: AbdulWahab A, et al.
Published: (2014-11-01)

Phenotypic and genotypic characteristics of Pseudomonas aeruginosa isolated from cystic fibrosis patients with chronic infections
by: Agnieszka Iwańska, et al.
Published: (2023-07-01)

Interplay between biofilm microenvironment and pathogenicity of Pseudomonas aeruginosa in cystic fibrosis lung chronic infection
by: Olivier Guillaume, et al.
Published: (2022-12-01)

Interaction between Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis
by: Jingming Zhao, et al.
Published: (2018-11-01)

Adherence of Pseudomonas aeruginosa to cystic fibrosis buccal epithelial cells
by: Meike Lingner, et al.
Published: (2017-01-01)

The Effect of Strict Segregation on Pseudomonas aeruginosa in Cystic Fibrosis Patients.
by: Rosa van Mansfeld, et al.
Published: (2016-01-01)

Recent advances in the treatment of <it>Pseudomonas aeruginosa </it>infections in cystic fibrosis
by: Høiby Niels
Published: (2011-04-01)

Catabolism of Nucleic Acids by a Cystic Fibrosis Pseudomonas aeruginosa Isolate: An Adaptive Pathway to Cystic Fibrosis Sputum Environment
by: Sheemal Shanista Kumar, et al.
Published: (2019-05-01)

Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives
by: Schmidt BZ, et al.
Published: (2016-09-01)

Therapeutic Approach of Chronic <i>Pseudomonas</i> Infection in Cystic Fibrosis—A Network Meta-Analysis
by: Orsolya Varannai, et al.
Published: (2021-08-01)

Nitrous oxide production in sputum from cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
by: Hansen, Christine Rønne, et al.
Published: (2014)

PFGE and antibiotic susceptibility phenotype analysis of Pseudomonas aeruginosa strain chronically infecting Cystic Fibrosis patients
by: Giovanna Pulcrano, et al.
Published: (2008-09-01)

Epidemiological significance of genome variations in Pseudomonas aeruginosa causing chronic lung infection in patients with cystic fibrosis
by: Shaginyan I.A., et al.
Published: (2019-12-01)

Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient.
by: Matthew L Workentine, et al.
Published: (2013-01-01)

Clinical outcomes of cystic fibrosis patients with Pseudomonas aeruginosa bloodstream infection
by: Andrei Zidaru, et al.
Published: (2022-06-01)

Bilateral Pseudomonas aeruginosa keratitis as presenting feature in an infant of cystic fibrosis
by: Meena Lakshmipathy, et al.
Published: (2022-01-01)

Estrogen aggravates inflammation in <it>Pseudomonas aeruginosa </it>pneumonia in cystic fibrosis mice
by: Gagnon Stéphane, et al.
Published: (2010-11-01)

The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages.
by: Christiane Essoh, et al.
Published: (2013-01-01)

Antibiotic Susceptibility of Pseudomonas Aeruginosa Isolated from Cystic Fibrosis Patients
by: Soltan Dallal, MM, et al.
Published: (2015-01-01)

Antibacterial and Antibiofilm Effects of Lactobacilli Strains against Clinical Isolates of <i>Pseudomonas aeruginosa</i> under Conditions Relevant to Cystic Fibrosis
by: Giovanna Batoni, et al.
Published: (2023-07-01)

Response to inhaled ceftazidime in patients with non‐cystic fibrosis bronchiectasis and chronic bronchial infection unrelated to Pseudomonas aeruginosa
by: Vanessa Riveiro, et al.
Published: (2022-11-01)

Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis
by: John Lam, et al.
Published: (2013-11-01)

Genomic properties in Achromobacter spp. strains from cystic fibrosis patients in Russia
by: Bocharova Y.A., et al.
Published: (2021-09-01)

Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis
by: Howlin, RP, et al.
Published: (2017)

Adeno-associated virus for cystic fibrosis gene therapy
by: S.V. Martini, et al.
Published: (2011-11-01)

Giving Drugs a Second Chance: Antibacterial and Antibiofilm Effects of Ciclopirox and Ribavirin against Cystic Fibrosis <i>Pseudomonas aeruginosa</i> Strains
by: Giovanni Di Bonaventura, et al.
Published: (2022-04-01)

Pooling isolates to address the diversity in antimicrobial susceptibility of Pseudomonas aeruginosa in cystic fibrosis
by: Sara Van den Bossche, et al.
Published: (2023-12-01)

Bile effects on the Pseudomonas aeruginosa pathogenesis in cystic fibrosis patients with gastroesophageal reflux
by: Mobina Bayat, et al.
Published: (2023-11-01)

22: GENOMIC EPIDEMIOLOGY OF PSEUDOMONAS AERUGINOSA IN CYSTIC FIBROSIS PATIENTS IN WESTERN AUSTRALIA
by: Daniel Knight, Dr, et al.
Published: (2022-11-01)